1. United States Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc

671.11
USD
-6.28
(-0.93%)
18.65EPS
26.96P/E
185.54BMarket Cap
Feb 04Next Earn
Thermo Fisher Scientific Inc
LSE:0R0H
(London Stock Exchange)

Recent

price

671.11

P/E

ratio

26.96

div

yld

0.26%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
25.77
30.35
34.39
36.33
42.41
42.55
46.29
52.96
60.59
63.86
81.36
99.52
114.58
111.03
112.25
118.19
123.81
Revenue per Share
2.57
3.49
3.24
3.53
4.76
4.95
5.12
5.63
7.31
9.24
16.1
19.61
17.73
15.53
16.58
17.78
18.62
Basic EPS, GAAP
3.07
3.76
4.74
4.8
5.5
6.32
7.13
8.85
9.42
10.12
17.21
17.23
17.63
17.95
19.02
16.69
19.55
Free Cash Flow per Basic Share
- -
- -
0.39
0.6
0.59
0.6
0.6
0.6
0.66
0.74
0.85
1
1.16
1.35
1.53
1.69
1.77
Dividend per Share
39.25
40.49
43.26
46.57
51.31
53.42
54.75
63.32
68.6
74.42
86.99
103.42
112.62
120.87
130.22
141.96
142.48
Book Value per Share
1.15
-12.79
-13.47
-7.51
-30.98
-25.61
-34.97
-41.27
-31.68
-25.21
-10.64
-53.86
-37.54
-36.09
-30.99
-31.35
-56.14
Tangible Book Value per Share
403
381
364
360
398
399
395
395
402
400
396
394
392
386
382
377
374
Basic Weighted Avg Shares
10,393
11,559
12,510
13,090
16,890
16,965
18,274
20,918
24,358
25,542
32,218
39,211
44,915
42,857
42,879
44,557
46,336
Sales/Revenue/Turnover
12.01
11.66
12.5
12.89
11.28
14.45
14.49
14.61
15.74
16.37
24.5
26.08
18.94
17.08
18
18.2
18.29
Operating Margin (%)
746
860
984
1,000
1,685
1,688
1,758
2,033
2,267
2,277
2,325
2,592
3,381
3,406
3,108
2,780
2,942
Depreciation Expense
1,036
1,330
1,178
1,273
1,894
1,975
2,022
2,225
2,938
3,696
6,375
7,725
6,950
5,995
6,335
6,704
6,967
Net Income, GAAP
9.34
9.66
0.87
3.06
9.18
- -
- -
8.28
9.93
9.18
11.76
12.54
8.97
4.51
9.34
7.48
7.82
Effective Tax Rate (%)
9.96
11.51
9.42
9.73
11.22
11.64
11.06
10.64
12.06
14.47
19.79
19.7
15.47
13.99
14.77
15.05
15.04
Profit Margin (%)
2,425
1,709
2,742
6,755
1,190
1,595
2,155
2,373
4,478
5,696
11,653
6,677
8,219
10,577
8,805
13,518
8,296
Working Capital
2,031
5,755
7,031
9,500
12,352
11,420
15,372
18,873
17,719
17,076
19,107
32,333
28,909
31,308
29,061
35,852
39,181
LT Debt
15,361
15,038
15,465
16,856
20,548
21,350
21,540
25,413
27,586
29,675
34,517
40,977
44,148
46,842
49,672
53,536
52,808
Total Equity
6.13
5.72
6.6
6.26
7.27
- -
- -
6.42
7.35
8.9
13.3
13.31
9.91
8.19
8.2
8.26
8.3
Return on Invested Capital (%)
6.34
7.52
6.35
6.12
7.46
- -
- -
6.54
7.61
9.17
13.24
12.4
9.84
9.16
9.33
9.2
9.16
Return on Capital (%)
6.73
8.75
7.72
7.88
10.13
9.43
9.43
9.48
11.09
12.91
19.87
20.52
16.4
13.22
13.15
13.02
13.5
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,533
3,090
3,368
LT Borrowings
35,852
40,071
39,181
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
376
372
370
Market Capitalization
218,945
182,184
185,543

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
28,707
22,316
23,365
Cash, Cash Equivalents & STI
10,105
3,256
4,064
Accounts Receivable, Net
8,900
9,204
9,451
Inventories
5,425
5,496
5,627
Total Current Liabilities
15,189
14,621
15,069
Payables & Accruals
8,946
8,603
8,785
ST Debt
3,533
3,090
3,368
Deferred Revenue
2,710
2,928
2,918

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.77%
9.28%
7.78%
Free Cash Flow
11.27%
-1.37%
-13.4%
Net Income, GAAP
15.16%
1.78%
5.82%
Sales/Revenue/Turnover
10.53%
7.13%
3.91%
Total Cash Common Dividend
10.36%
13.58%
9.09%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,345
10,541
10,598
11,395
42,879
2025
10,364
10,854
11,122
12,215
44,557
2026
11,005
11,994
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.48
4.05
4.27
4.79
16.58
2025
3.99
4.28
4.28
5.22
17.78
2026
4.44
4.68
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.39
0.39
0.39
1.53
2025
0.39
0.43
0.43
0.43
1.69
2026
0.44
0.47
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Medtronic plc. (NYSE:MDT)
Business
Thermo Fisher Scientific Inc. (NYSE: TMO) provides analytical instruments, equipment, software, services, consumables, and reagents for research, analysis, discovery, and diagnostics worldwide. The company offers products including mass spectrometry systems, chromatography instruments, genetic analysis tools, bioprocessing equipment, clinical diagnostics assays, laboratory automation solutions, and electron microscopy technologies; its key brands encompass Thermo Scientific, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon. Headquartered in Waltham, Massachusetts, Thermo Fisher was originally founded in 1902 through the merger of Fisher Scientific and Thermo Electron in 2006, and operates in over 70 countries serving pharmaceutical, biotechnology, academic, government, and healthcare customers across life sciences, analytical technologies, specialty diagnostics, and laboratory products segments. Recently, the company expanded its capabilities through the acquisition of Olink Holding AB in 2024 to bolster proteomics offerings, launched the new Orbitrap Astral mass spectrometer in late 2024 for high-throughput proteomics, and formed strategic partnerships including a multi-year collaboration with AstraZeneca to advance biomarker discovery; in 2025, Thermo Fisher announced expansions in gene editing technologies and sustainable manufacturing initiatives amid ongoing supply chain optimizations.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Thermo Fisher: You Don't Need A Microscope To See The Growth Anymore

  • fool.com

    Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors

  • gurufocus.com

    Thermo Fisher Stocks Rise 1.0% as Revenue Growth Beats Estimates

  • benzinga.com

    Nasdaq Gains 1%; Thermo Fisher Scientific Posts Upbeat Earnings

  • seekingalpha.com

    Thermo Fisher Scientific Inc. (TMO) Q3 2026 Earnings Call Transcript

  • zacks.com

    TMO Q3 Earnings & Revenues Beat Estimates, Stock Down in Pre-Market

  • zacks.com

    Compared to Estimates, Thermo Fisher (TMO) Q3 Earnings: A Look at Key Metrics

  • seekingalpha.com

    Thermo Fisher Q3: The Recovery Is Real, And I'm Still Buying

  • marketbeat.com

    Thermo Fisher Scientific Q3 Earnings Call Highlights

  • proactiveinvestors.com

    Thermo Fisher posts higher third-quarter revenue and earnings as margins improve

  • zacks.com

    Thermo Fisher Scientific (TMO) Tops Q3 Earnings and Revenue Estimates

  • businesswire.com

    Thermo Fisher Scientific Reports Third Quarter 2026 Results

  • zacks.com

    Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again

  • benzinga.com

    Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings

  • invezz.com

    Two stocks poised to benefit from rotation out of AI

  • gurufocus.com

    TMO DCF Analysis: Intrinsic Value $421 vs Price $690

  • defenseworld.net

    Banque Pictet & Cie SA Sells 6,618 Shares of Thermo Fisher Scientific Inc. $TMO

  • zacks.com

    What Analyst Projections for Key Metrics Reveal About Thermo Fisher (TMO) Q3 Earnings

  • benzinga.com

    Pfizer, Thermo Fisher Scientific And More: CNBC's ‘Final Trades'

  • zacks.com

    Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth